Medicenna Therapeutics Corp. NASDAQ:MDNA

Medicenna Therapeutics Corp. stock price today

$0.157
-0.00
-0.32%
Financial Health
0
1
2
3
4
5
6
7
8
9

Medicenna Therapeutics Corp. stock price monthly change

-46.76%
month

Medicenna Therapeutics Corp. stock price quarterly change

-65.82%
quarter

Medicenna Therapeutics Corp. stock price yearly change

-78.56%
year

Medicenna Therapeutics Corp. key metrics

Market Cap
N/A
Enterprise value
N/A
P/E
-5.45
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
1.58
PEG ratio
0.18
EPS
-0.38
Revenue
N/A
EBITDA
-17.95M
Income
-22.19M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Medicenna Therapeutics Corp. stock price history

Medicenna Therapeutics Corp. stock forecast

Medicenna Therapeutics Corp. financial statements

Medicenna Therapeutics Corp. (NASDAQ:MDNA): Profit margin
Sep 2021 0 -8.17M
Dec 2021 0 -4.80M
Mar 2022 0 -3.20M
Mar 2023 0 -6.00M
Medicenna Therapeutics Corp. (NASDAQ:MDNA): Analyst Estimates
2026 1.37M -23.46M -1706.42%
2027 600K -19.55M -3258.4%
  • Analysts Price target

  • Financials & Ratios estimates

Medicenna Therapeutics Corp. (NASDAQ:MDNA): Earnings per share (EPS)
2023-11-03 -0.05 -0.05
Medicenna Therapeutics Corp. (NASDAQ:MDNA): Debt to assets
Jun 2022 20140000 2.14M 10.66%
Sep 2022 42560000 8.64M 20.31%
Dec 2022 38174000 4.94M 12.96%
Mar 2023 36446000 6.96M 19.1%
Medicenna Therapeutics Corp. (NASDAQ:MDNA): Cash Flow
Sep 2021 -9.33M 0 61K
Dec 2021 -6.77M 10.01M 3.47M
Mar 2022 -2.89M 0 85K
Mar 2023 -2.29M 0 -189K

Medicenna Therapeutics Corp. alternative data

Medicenna Therapeutics Corp. (NASDAQ:MDNA): Employee count
Aug 2023 16
Sep 2023 16
Oct 2023 16
Nov 2023 16
Dec 2023 16
Jan 2024 16
Feb 2024 16
Mar 2024 16
Apr 2024 16
May 2024 16
Jun 2024 16
Jul 2024 16

Medicenna Therapeutics Corp. other data

11.64% -9.34%
of MDNA is owned by hedge funds
6.31M -5.06M
shares is hold by hedge funds
Friday, 13 December 2024
globenewswire.com
Thursday, 5 December 2024
globenewswire.com
Wednesday, 27 November 2024
globenewswire.com
Monday, 25 November 2024
globenewswire.com
Wednesday, 13 November 2024
globenewswire.com
Thursday, 26 September 2024
globenewswire.com
Thursday, 15 August 2024
globenewswire.com
Thursday, 1 August 2024
globenewswire.com
Monday, 22 July 2024
seekingalpha.com
Friday, 31 May 2024
globenewswire.com
Wednesday, 22 May 2024
globenewswire.com
Thursday, 9 November 2023
GlobeNewsWire
Monday, 30 October 2023
InvestorPlace
Thursday, 28 September 2023
GlobeNewsWire
Tuesday, 18 April 2023
GlobeNewsWire
Tuesday, 28 February 2023
Seeking Alpha
Tuesday, 7 February 2023
Seeking Alpha
Tuesday, 31 January 2023
GlobeNewsWire
Thursday, 26 January 2023
GlobeNewsWire
Friday, 4 November 2022
Seeking Alpha
Tuesday, 25 October 2022
GlobeNewsWire
Friday, 19 August 2022
Finbold
Monday, 15 August 2022
Seeking Alpha
Friday, 5 August 2022
GlobeNewsWire
Wednesday, 22 June 2022
Seeking Alpha
Tuesday, 7 June 2022
GlobeNewsWire
  • What's the price of Medicenna Therapeutics Corp. stock today?

    One share of Medicenna Therapeutics Corp. stock can currently be purchased for approximately $0.16.

  • When is Medicenna Therapeutics Corp.'s next earnings date?

    Unfortunately, Medicenna Therapeutics Corp.'s (MDNA) next earnings date is currently unknown.

  • Does Medicenna Therapeutics Corp. pay dividends?

    No, Medicenna Therapeutics Corp. does not pay dividends.

  • What is Medicenna Therapeutics Corp.'s stock symbol?

    Medicenna Therapeutics Corp. is traded on the NASDAQ under the ticker symbol "MDNA".

  • What is Medicenna Therapeutics Corp.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Medicenna Therapeutics Corp.?

    Shares of Medicenna Therapeutics Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Medicenna Therapeutics Corp. have?

    As Jul 2024, Medicenna Therapeutics Corp. employs 16 workers.

  • When Medicenna Therapeutics Corp. went public?

    Medicenna Therapeutics Corp. is publicly traded company for more then 7 years since IPO on 13 Nov 2017.

  • What is Medicenna Therapeutics Corp.'s official website?

    The official website for Medicenna Therapeutics Corp. is medicenna.com.

  • Where are Medicenna Therapeutics Corp.'s headquarters?

    Medicenna Therapeutics Corp. is headquartered at 2 Bloor Street West, Toronto, ON.

  • How can i contact Medicenna Therapeutics Corp.?

    Medicenna Therapeutics Corp.'s mailing address is 2 Bloor Street West, Toronto, ON and company can be reached via phone at +41 66485555.

Medicenna Therapeutics Corp. company profile:

Medicenna Therapeutics Corp.

medicenna.com
Exchange:

NASDAQ

Full time employees:

16

Industry:

Biotechnology

Sector:

Healthcare

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

2 Bloor Street West
Toronto, ON M4W 3E2

CIK: 0001807983
ISIN: CA58490H1073
CUSIP: 58490H107